Hypoglycemia-Pipeline Review, H2 2015

Hypoglycemia-Pipeline Review, H2 2015

  • Products Id :- GMDHC7030IDB
  • |
  • Pages: 64
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Hypoglycemia-Pipeline Review, H2 2015


Global Markets Direct's, 'Hypoglycemia-Pipeline Review, H2 2015', provides an overview of the Hypoglycemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypoglycemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoglycemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Hypoglycemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hypoglycemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hypoglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hypoglycemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hypoglycemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hypoglycemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Hypoglycemia Overview 7

Therapeutics Development 8

Pipeline Products for Hypoglycemia-Overview 8

Pipeline Products for Hypoglycemia-Comparative Analysis 9

Hypoglycemia-Therapeutics under Development by Companies 10

Hypoglycemia-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Hypoglycemia-Products under Development by Companies 14

Hypoglycemia-Companies Involved in Therapeutics Development 15

Biodel Inc. 15

Eli Lilly and Company 16

Heptares Therapeutics Limited 17

Novartis AG 18

SkyePharma Plc 19

USV Limited 20

XERIS Pharmaceuticals, Inc. 21

XOMA Corporation 22

Zealand Pharma A/S 23

Hypoglycemia-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

Biologic for Hypoglycemia-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

glucagon-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

glucagon-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

glucagon-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

glucagon-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

glucagon-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

pasireotide-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

terbutaline sulphate-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

XOMA-358-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

ZP-4207-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Hypoglycemia-Recent Pipeline Updates 47

Hypoglycemia-Dormant Projects 53

Hypoglycemia-Discontinued Products 54

Hypoglycemia-Product Development Milestones 55

Featured News & Press Releases 55

Jun 26, 2015: Phase I trial results for Zealand's glucagon analogue, ZP4207 support its further development as a ready-to-use rescue treatment for severe hypoglycemia in diabetes patients on insulin therapy 55

Jun 23, 2015: Zosano Pharma Completes Enrollment in Phase 2 Trial for ZP-Glucagon, Its Microneedle Patch for Treatment of Severe Hypoglycemia 56

May 20, 2015: Zealand starts clinical development of a multiple-dose version of its stable glucagon analogue, ZP4207 56

Mar 16, 2015: Biodel's Glucagon Formulation for Use in a Proprietary Auto-Reconstitution Device for the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint in Phase 1 Clinical Trial 57

Mar 07, 2015: XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting 59

Mar 05, 2015: XOMA Will Present XOMA 358 Phase 1 Data at ENDO 2015 59

Dec 04, 2014: Biodel Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program 60

Nov 17, 2014: Zealand advances its proprietary stable glucagon analogue for severe hypoglycemia in diabetes into clinical development 60

Jun 17, 2014: Zealand presented new data on ZP-GA-1 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association's (ADA) 74th Scientific Sessions 61

Jul 03, 2013: Biodel to Present New Preclinical Glucagon Data During Corporate Overview at JMP Securities Healthcare Conference 62

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 6

List of Tables

Number of Products under Development for Hypoglycemia, H2 2015 8

Number of Products under Development for Hypoglycemia-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Late Stage Development, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Development, H2 2015 13

Products under Development by Companies, H2 2015 14

Hypoglycemia-Pipeline by Biodel Inc., H2 2015 15

Hypoglycemia-Pipeline by Eli Lilly and Company, H2 2015 16

Hypoglycemia-Pipeline by Heptares Therapeutics Limited, H2 2015 17

Hypoglycemia-Pipeline by Novartis AG, H2 2015 18

Hypoglycemia-Pipeline by SkyePharma Plc, H2 2015 19

Hypoglycemia-Pipeline by USV Limited, H2 2015 20

Hypoglycemia-Pipeline by XERIS Pharmaceuticals, Inc., H2 2015 21

Hypoglycemia-Pipeline by XOMA Corporation, H2 2015 22

Hypoglycemia-Pipeline by Zealand Pharma A/S, H2 2015 23

Assessment by Monotherapy Products, H2 2015 24

Number of Products by Stage and Target, H2 2015 26

Number of Products by Stage and Mechanism of Action, H2 2015 28

Number of Products by Stage and Route of Administration, H2 2015 30

Number of Products by Stage and Molecule Type, H2 2015 32

Hypoglycemia Therapeutics-Recent Pipeline Updates, H2 2015 47

Hypoglycemia-Dormant Projects, H2 2015 53

Hypoglycemia-Discontinued Products, H2 2015 54

List of Figures

Number of Products under Development for Hypoglycemia, H2 2015 8

Number of Products under Development for Hypoglycemia-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Clinical Stage Development, H2 2015 12

Comparative Analysis by Early Stage Products, H2 2015 13

Assessment by Monotherapy Products, H2 2015 24

Number of Products by Top 10 Targets, H2 2015 25

Number of Products by Stage and Top 10 Targets, H2 2015 25

Number of Products by Top 10 Mechanism of Actions, H2 2015 27

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 27

Number of Products by Top 10 Routes of Administration, H2 2015 29

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 29

Number of Products by Top 10 Molecule Types, H2 2015 31

Number of Products by Stage and Top 10 Molecule Types, H2 2015 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Biodel Inc.

Eli Lilly and Company

Heptares Therapeutics Limited

Novartis AG

SkyePharma Plc

USV Limited

XERIS Pharmaceuticals, Inc.

XOMA Corporation

Zealand Pharma A/S

Hypoglycemia Therapeutic Products under Development, Key Players in Hypoglycemia Therapeutics, Hypoglycemia Pipeline Overview, Hypoglycemia Pipeline, Hypoglycemia Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com